DELFI Diagnostics
Biotechnology ResearchMaryland, United States51-200 Employees
DELFI uses artificial intelligence and whole genome sequencing to sensitively detect unique patterns of DNA fragmentation in the blood of patients with cancer.
Partnerships and Collaborations DELFI Diagnostics has established key partnerships and collaborations with prominent companies like Merck Global Health Innovation Fund and Immunocore Ltd., indicating potential sales opportunities through leveraging these relationships for mutual growth.
Expansion in Healthcare Settings Integration of DELFI Diagnostics' FirstLook Lung test into primary care settings at various locations showcases a growing demand for their blood-based screening tools, creating opportunities for sales expansion in healthcare facilities.
Financial Health and Funding With a revenue ranging between $10M - $50M and funding of $225M, DELFI Diagnostics is financially stable, signaling a strong potential for sales growth and investment in their innovative biotechnology research solutions.
Cancer Monitoring Blood Test Launch The recent launch of a cancer-monitoring blood test by DELFI Diagnostics alongside collaborations with Immunocore opens doors for sales representatives to promote this innovative assay that may improve cancer treatment monitoring, catering to a critical need in the market.
Cutting-Edge Technology Utilization DELFI Diagnostics employs cutting-edge technologies like artificial intelligence and whole genome sequencing, along with a tech stack including Kubernetes, TensorFlow, and Java, providing a unique selling point for sales professionals to position their solutions as industry-leading and technologically advanced.
DELFI Diagnostics uses 8 technology products and services including Kubernetes, Jamf, Atlassian Jira, and more. Explore DELFI Diagnostics's tech stack below.
DELFI Diagnostics Email Formats | Percentage |
Last@delfidiagnostics.com | 69% |
First.Last@delfidiagnostics.com | 30% |
Middle@delfidiagnostics.com | 1% |
Biotechnology ResearchMaryland, United States51-200 Employees
DELFI uses artificial intelligence and whole genome sequencing to sensitively detect unique patterns of DNA fragmentation in the blood of patients with cancer.
DELFI Diagnostics has raised a total of $225M of funding over 3 rounds. Their latest funding round was raised on Jul 18, 2022 in the amount of $225M.
DELFI Diagnostics's revenue is in the range of $10M$50M
DELFI Diagnostics has raised a total of $225M of funding over 3 rounds. Their latest funding round was raised on Jul 18, 2022 in the amount of $225M.
DELFI Diagnostics's revenue is in the range of $10M$50M